Impact AstraZenecon's $1 billion anti-thrombosis drug! Colum, Luo Xin more than 20 pharmaceutical companies reported production.

Pharmaceutical Network September 27th, September 24th, CDE official website shows that Chengdu Bett Pharmaceuticals' Tegrelo tablets to copy 4 categories of applications for listing was accepted.
2019 in China's public medical institutions terminal sales of more than 1.5 billion yuan, of which AstraZeneta's market share accounted for more than 95%.
There are already 8 generic pharmaceutical companies, such as Stone Pharmaceutical Group, Ouyi Pharmaceuticals, Nanjing Zhengda Tianqing, Zhejiang Haizheng Pharmaceuticals, Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceuticals, etc., and have been evaluated.
addition, there are more than 20 enterprises such as Sichuan Colum Pharmaceuticals, Guangdong Dongsan Pharmaceuticals and Shandong Luoxin Pharmaceuticals, which have declared their listings in the review and approval process (in the drug review center).
data show that tigrillo tablets are mainly used in the treatment of acute coronary artery syndrome (ACS), reducing the incidence of cardiovascular death, myocardial infarction and stroke in ACS patients or patients with a history of myocardial infarction (MI).
In recent years, China's public medical institutions terminal for Grelo film sales (units: 100 million yuan) Source: Minet China's public medical institutions terminal competition pattern Minet data show that in recent years, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal Grelo film sales increased rapidly, breaking the 1 billion mark in 2018;
, AstraZeneta has a market share of more than 95 per cent.
Source: Minet MED2.0 China Drug Review Database up to now, in addition to the import of AstraZeneta tablets, the domestic stone pharmaceutical group Ohi Pharmaceuticals, Nanjing Zhengda Tianqing, Zhejiang Haizheng Pharmaceuticals, Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceuticals and other 8 generic pharmaceutical enterprises, and have been evaluated.
addition, there are more than 20 enterprises such as Sichuan Colum Pharmaceuticals, Guangdong Dongsan Pharmaceuticals, Lepu Pharmaceuticals, Shandong Luoxin Pharmaceuticals, etc. declared for listing in the review and approval (in the drug review center).
It is understood that for the third batch of Grelo tablets collected varieties, the winning enterprises for Xinlitai, Nanjing Zhengda Tianqing, Haizheng Pharmaceuticals, Yangzijiang Pharmaceutical Group, Shi Pharmaceutical Group and Huilun Pharmaceuticals and other 6.
.